X
<

Where Is Novartis Positioned after 3Q17?

PART:
1 2 3 4 5 6 7 8 9 10 11 12
Part 8
Where Is Novartis Positioned after 3Q17? PART 8 OF 12

How Novartis’s Tasigna Is Looking Now

Tasigna revenue trends

In 3Q17, Novartis’s (NVS) Tasigna reported revenues of $482 million, which was ~9% higher YoY (year-over-year) and 4% higher QoQ (quarter-over-quarter). Sales growth in the US and emerging markets primarily attributed to the revenue growth of Novartis in 3Q17.

How Novartis’s Tasigna Is Looking Now

Interested in VYMI? Don't miss the next report.

Receive e-mail alerts for new research on VYMI

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

ENTESTfreedom and ENTESTop trials

In June 2017, Novartis presented the results from the additional analysis of its phase-3 ENESTfreedom and ENESTop trials. The phase-3 ENESTfreedom and ENESTop trial demonstrated that around half of adult individuals with Philadelphia chromosome-positive chronic myeloid leukemia (or CML) in the chronic phase who discontinued Tasigna remained in treatment-free remission (or TFR) for approximately two years after stopping therapy.

The ENTESTfreedom trial evaluated the potential of discontinuation of Tasigna therapy in eligible candidates with Philadelphia chromosome-positive chronic myeloid leukemia (or CML) who achieved a sustained deep molecular response (or DMR) after a minimum of three years of first-line Tasigna therapy.

In the marketplace, Novartis Tasigna competes with Bristol-Myers Squibb’s (BMY) Sprycel, Pfizer’s (PFE) Bosulif, and Takeda Pharmaceuticals’ (TKPYY) Iclusig. In 3Q17, Sprycel reported revenues of ~$509 million. The Vanguard International High Dividend Yield ETF (VYMI) has ~1.18% of its total portfolio holdings in NVS.

X

Please select a profession that best describes you: